A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
- Determine the overall 2-year survival rate after radiofrequency ablation (RFA) of lung
nodules in high-risk patients with stage IA non-small cell lung cancer.
- Determine freedom from regional or distant recurrence in patients treated with this
- Determine freedom from local recurrence in the ablated lobe at 2 years in these
- Determine the number of procedures deemed technical successes in patients treated with
- Determine procedure-specific morbidity and mortality.
- Determine the utility of immediate (within 96 hours) post-RFA positron emission
tomography (PET) in predicting overall survival and local control in these patients.
- Determine the effect of RFA on short-term (3 months post-RFA) and long-term (24 months
post-RFA) pulmonary function in these patients.
OUTLINE: This is a multicenter, pilot study.
A radiofrequency electrode is placed by CT guidance into the target tumor. Patients undergo
radiofrequency ablation (RFA) directly to the tumor for up to 12 minutes to obtain an
intratumoral temperature > 60°C. Patients may receive 3 RFA treatments (a total of 36
minutes) to obtain the target temperature. Patients undergo fludeoxyglucose F18 positron
emission tomography within 24-96 hours after the final treatment.
After completion of study treatment, patients are followed every 3 months for 1 year and
then every 6 months for 1 year.
PROJECTED ACCRUAL: A total of 55 patients will be accrued for this study within 20 months.
Primary Purpose: Treatment
Overall survival at 2 years
Damian E. Dupuy, MD
Rhode Island Hospital
United States: Federal Government
|Medical City Dallas Hospital||Dallas, Texas 75230|
|Medical College of Wisconsin Cancer Center||Milwaukee, Wisconsin 53226|
|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill||Chapel Hill, North Carolina 27599-7570|
|University of California Davis Cancer Center||Sacramento, California 95817|
|Stony Brook University Cancer Center||Stony Brook, New York 11794-8174|
|Rhode Island Hospital Comprehensive Cancer Center||Providence, Rhode Island 02903|
|Providence Cancer Center at Sacred Heart Medical Center||Spokane, Washington 99220-2555|
|William Beaumont Hospital - Royal Oak Campus||Royal Oak, Michigan 48073|
|Jonsson Comprehensive Cancer Center at UCLA||Los Angeles, California 90095-1781|
|Huntsman Cancer Institute at University of Utah||Salt Lake City, Utah 84112|
|Providence Cancer Center at Providence Portland Medical Center||Portland, Oregon 97213-2967|
|Providence Cancer Center at Holy Family Hospital||Spokane, Washington 99207|
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|
|UAB Comprehensive Cancer Center||Birmingham, Alabama 35294|
|Boston University Cancer Research Center||Boston, Massachusetts 02118|
|Good Samaritan Hospital Cancer Treatment Center||Cincinnati, Ohio 45220|
|H. Clay Evans Johnson Cancer Center at Memorial Hospital||Chattanooga, Tennessee 37404|